A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non–small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design

Treatment with poly ADP ribose polymerase (PARP)1/2 inhibitors represents a novel opportunity to selectively kill a subset of cancer cell types by exploiting their deficiencies in DNA repair, thus leading to synthetic lethality. Treatment of homologous recombination deficient (HRD)-tumors with PARP...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical lung cancer 2021-01, Vol.22 (1), p.e63-e66
Hauptverfasser:	Passiglia, Francesco, Bironzo, Paolo, Righi, Luisella, Listì, Angela, Arizio, Francesca, Novello, Silvia, Volante, Marco, Scagliotti, Giorgio Vittorio
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use B7-H1 Antigen - metabolism Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Clinical Trials, Phase II as Topic - methods DNA Repair Enzymes - genetics Germ-Line Mutation Homologous recombination repair deficiency Humans Indazoles - administration & dosage Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - pathology Mesothelioma, Malignant - drug therapy Mesothelioma, Malignant - genetics Mesothelioma, Malignant - pathology Mutation PARP inhbitors PD-1 inhibitors PD-L1 Piperidines - administration & dosage Pleural Neoplasms - drug therapy Pleural Neoplasms - genetics Pleural Neoplasms - pathology Prognosis Prospective Studies Treatment combinations
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!